NEW YORK (GenomeWeb) – Horizon Discovery reported on Tuesday that its preliminary 2017 revenues rose 52 percent year over year, thanks largely to a 101 percent increase in product revenues.

For the 12 months ended Dec. 31, the gene editing firm said revenues rose to £36.5 million ($49.2 million) from £24.1 million in 2016. Organic revenues excluding the acquisition of Dharmacon increased 14 percent to £27.5 million.

Product revenues rose to £22.8 million while services revenues increased 7 percent to £13.7 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.